NCT05292040View on ClinicalTrials.gov

A Study of LY3857210 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions

Healthy

Interventions

DRUG

LY3857210

Administered orally.

Trial Locations (1)

06510

Invicro, Institute for Neurodegenerative Disorders, New Haven

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY